Visnagin mitigates acute kidney injury caused by lipopolysaccharide administration by inhibiting the NF-κB and pyroptosis pathways
Visnagin mitigates LPS-induced AKI by targeting multiple signalling pathways, particularly NF-κB-mediated inflammation and NLRP3 inflammasome-mediated pyroptosis. These findings suggest that visnagin is a promising multitarget candidate for treating sepsis-associated AKI.
Authors
- Chen‐Yu Chiang (ORCID: https://orcid.org/0009-0002-0595-130X)
- Chien‐Ying Lee (ORCID: https://orcid.org/0000-0001-8159-4645)
- Ching-Chi Tseng
- Wen‐Ying Chen (ORCID: https://orcid.org/0000-0002-5105-5285)
- Sheng‐Wen Wu (ORCID: https://orcid.org/0000-0002-2978-8626)
- Yu‐Hsiang Kuan (ORCID: https://orcid.org/0000-0002-8991-6394)
- Shiuan‐Shinn Lee
- Chun‐Jung Chen
Institutions
- National Chung Hsing University (TW)
- Taichung Veterans General Hospital (TW)
- Chung Shan Medical University Hospital (TW)
- Shenzhen Municipal People's Government (CN)
- Chung Shan Medical University (TW)
Publication Details
- Journal
- Biomedicine & Pharmacotherapy
- Published
- 2025-09-23
- DOI
- https://doi.org/10.1016/j.biopha.2025.118578
- Citations
- 1
- Primary Topic
- Inflammasome and immune disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.81